IDEAYA Biosciences (IDYA) vs Parabilis Medicines (PBLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
IDEAYA Biosciences is the larger company by market cap ($3.48 billion vs $3.47 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDYA | PBLS |
|---|---|---|
| Share price | $36.06 | $28.09 |
| Market cap | $3.48B | $3.47B |
| 1-day change | -0.55% | -2.53% |
| YTD return | +4.31% | — |
| 1-year return | +34.35% | — |
| 5-year return | +55.90% | — |
| EPS (TTM) | $-1.94 | $-9.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $218.71M | — |
| Revenue growth (YoY) | +3024.43% | — |
| Net income (latest FY) | $-113.70M | — |
| Operating margin | -72.84% | — |
| Net margin | -51.99% | — |
| 52-week high | $42.68 | $42.49 |
| 52-week low | $26.05 | $24.51 |
| Distance from 52-week high | -15.51% | -33.89% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +46.28% | +48.63% |
| Average volume | 779.15K | 690.91K |
| Shares outstanding | 96.49M | 121.95M |
| Employees | 145 | 145 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: IDEAYA Biosciences in Healthcare and Parabilis Medicines in Health Care.
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Healthcare · Biotechnology · 145 employees
About Parabilis Medicines
PBLS stock →Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
IDYA vs PBLS FAQ
Which is bigger, IDEAYA Biosciences or Parabilis Medicines?
IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $3.48B compared with $3.47B for Parabilis Medicines (PBLS).
Are IDEAYA Biosciences and Parabilis Medicines in the same industry?
No. IDEAYA Biosciences is in the Healthcare sector, while Parabilis Medicines is in Health Care.